|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SOWAHC |
Gene summary for SOWAHC |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SOWAHC | Gene ID | 65124 |
| Gene name | sosondowah ankyrin repeat domain family member C | |
| Gene Alias | ANKRD57 | |
| Cytomap | 2q13 | |
| Gene Type | protein-coding | GO ID | NA | UniProtAcc | Q53LP3 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 65124 | SOWAHC | LZE4T | Human | Esophagus | ESCC | 1.85e-14 | -4.24e-01 | 0.0811 |
| 65124 | SOWAHC | LZE8T | Human | Esophagus | ESCC | 1.19e-09 | -5.31e-01 | 0.067 |
| 65124 | SOWAHC | LZE20T | Human | Esophagus | ESCC | 3.47e-07 | -4.71e-01 | 0.0662 |
| 65124 | SOWAHC | LZE22D1 | Human | Esophagus | HGIN | 7.79e-05 | -6.28e-01 | 0.0595 |
| 65124 | SOWAHC | LZE22T | Human | Esophagus | ESCC | 2.80e-06 | -4.52e-01 | 0.068 |
| 65124 | SOWAHC | LZE24T | Human | Esophagus | ESCC | 2.45e-09 | -4.02e-01 | 0.0596 |
| 65124 | SOWAHC | LZE21T | Human | Esophagus | ESCC | 6.09e-04 | -2.23e-01 | 0.0655 |
| 65124 | SOWAHC | LZE6T | Human | Esophagus | ESCC | 4.45e-06 | -4.81e-01 | 0.0845 |
| 65124 | SOWAHC | P2T-E | Human | Esophagus | ESCC | 4.81e-22 | -2.57e-01 | 0.1177 |
| 65124 | SOWAHC | P4T-E | Human | Esophagus | ESCC | 1.46e-07 | 1.88e-02 | 0.1323 |
| 65124 | SOWAHC | P5T-E | Human | Esophagus | ESCC | 1.88e-13 | 6.37e-01 | 0.1327 |
| 65124 | SOWAHC | P8T-E | Human | Esophagus | ESCC | 1.71e-11 | -3.68e-01 | 0.0889 |
| 65124 | SOWAHC | P9T-E | Human | Esophagus | ESCC | 1.95e-06 | 1.60e-01 | 0.1131 |
| 65124 | SOWAHC | P10T-E | Human | Esophagus | ESCC | 1.24e-10 | 6.12e-02 | 0.116 |
| 65124 | SOWAHC | P12T-E | Human | Esophagus | ESCC | 1.76e-27 | -3.08e-01 | 0.1122 |
| 65124 | SOWAHC | P15T-E | Human | Esophagus | ESCC | 8.46e-06 | -1.02e-01 | 0.1149 |
| 65124 | SOWAHC | P16T-E | Human | Esophagus | ESCC | 7.72e-27 | -5.01e-01 | 0.1153 |
| 65124 | SOWAHC | P17T-E | Human | Esophagus | ESCC | 2.21e-08 | -5.58e-01 | 0.1278 |
| 65124 | SOWAHC | P20T-E | Human | Esophagus | ESCC | 3.61e-16 | -4.99e-01 | 0.1124 |
| 65124 | SOWAHC | P21T-E | Human | Esophagus | ESCC | 1.52e-04 | 3.90e-01 | 0.1617 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SOWAHC | insertion | Nonsense_Mutation | novel | c.1447_1448insTGCTCAAGCTTGTTTGGATACGTAATCTATGA | p.His483LeufsTer11 | p.H483Lfs*11 | Q53LP3 | protein_coding | TCGA-A2-A0CX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | ||
| SOWAHC | SNV | Missense_Mutation | c.1358N>T | p.Ala453Val | p.A453V | Q53LP3 | protein_coding | tolerated(0.24) | benign(0.006) | TCGA-G4-6588-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| SOWAHC | deletion | Frame_Shift_Del | c.1577delN | p.Ter526%3D | p.*526%3D | Q53LP3 | protein_coding | TCGA-D5-6928-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |||
| SOWAHC | deletion | Frame_Shift_Del | rs766957308 | c.1493delN | p.Glu500ArgfsTer18 | p.E500Rfs*18 | Q53LP3 | protein_coding | TCGA-DM-A1HB-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | ||
| SOWAHC | deletion | Frame_Shift_Del | rs766957308 | c.1493delN | p.Glu500ArgfsTer18 | p.E500Rfs*18 | Q53LP3 | protein_coding | TCGA-NH-A5IV-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| SOWAHC | SNV | Missense_Mutation | novel | c.1007N>A | p.Ala336Asp | p.A336D | Q53LP3 | protein_coding | deleterious(0) | probably_damaging(0.985) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| SOWAHC | SNV | Missense_Mutation | novel | c.1252N>A | p.Val418Met | p.V418M | Q53LP3 | protein_coding | deleterious(0.02) | probably_damaging(0.972) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| SOWAHC | SNV | Missense_Mutation | novel | c.1189C>A | p.Leu397Met | p.L397M | Q53LP3 | protein_coding | tolerated(0.07) | probably_damaging(0.942) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| SOWAHC | SNV | Missense_Mutation | c.1373G>A | p.Arg458His | p.R458H | Q53LP3 | protein_coding | deleterious(0.01) | possibly_damaging(0.899) | TCGA-AX-A064-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SOWAHC | SNV | Missense_Mutation | novel | c.613N>A | p.Leu205Ile | p.L205I | Q53LP3 | protein_coding | deleterious(0.03) | benign(0.007) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |